Cycloastragenol Attenuates Osteoclastogenesis and Bone Loss by Targeting RANKL-Induced Nrf2/Keap1/ARE, NF-κB, Calcium, and NFATc1 Pathways

Osteoporosis, which typically affects postmenopausal women, is an osteolytic disease due to over-activation of osteoclasts. However, current drugs targeting osteoclast inhibition face various side effects, making natural compounds with great interest as alternative treatment options. Cycloastragenol...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Gang Wang, Chao Ma, Kai Chen, Ziyi Wang, Heng Qiu, Delong Chen, Jianbo He, Cheng Zhang, Ding Guo, Boyong Lai, Shuangxiao Zhang, Linfeng Huang, Fan Yang, Jinbo Yuan, Leilei Chen, Wei He, Jiake Xu
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2022-01-01
Ráidu:	Frontiers in Pharmacology
Fáttát:	cycloastragenol osteoclast RANKL Nfatc1 ROS
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fphar.2021.810322/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!